Free 2025 ACRP Certified Professional ACRP-CP dumps are available on Google Drive shared by DumpsActual
Welcome to download the newest DumpsActual ACRP-CP PDF dumps: https://exampdf.dumpsactual.com/ACRP-CP-actualtests-dumps.html ( 127 Q&As)
NEW QUESTION # 22
An impartial witness should be present during the entire informed consent discussion when:
- A. A subject has been determined to be vulnerable.
- B. A legally acceptable representative is unable to read.
- C. A parent/guardian is consenting for a minor subject.
- D. An interpreter is translating the consent form for a subject.
Answer: B
Explanation:
An impartial witness is required when a legally acceptable representative (LAR) or the subject themselves cannot read. The witness ensures that the information is presented accurately and that the consent process is conducted ethically. The witness also signs the consent form to confirm that the subject or representative understands the study details.
GCP guidelines require an impartial witness to be present to confirm that the consent information is correctly conveyed and understood when the subject or LAR cannot read.
"An impartial witness is required when the subject or legally acceptable representative is unable to read, ensuring the consent process is transparent and ethically sound." Objectives:
* Protect the rights of individuals with literacy challenges.
* Maintain ethical standards in the consent process.
NEW QUESTION # 23
A site is starting up a Phase III trial. They have received IRB/IEC approval and have scheduled the SIV. The site cannot begin enrolling subjects until:
- A. The site receives approval from the medical monitor to begin enrolling.
- B. The CRA has performed source document review and verification at the site.
- C. A signed clinical trial agreement between the site and sponsor is in place.
- D. The DSMB meets and the first DSMB meeting report has been issued.
Answer: C
Explanation:
Before a clinical trial site can begin enrolling participants, there must be a signed clinical trial agreement (CTA) between the site and the sponsor. This agreement outlines the responsibilities, financial arrangements, and expectations between both parties, ensuring that the trial is conducted in compliance with regulatory and ethical standards.
GCP guidelines require that a formal agreement be in place before trial initiation to protect the rights and obligations of both the sponsor and the site.
"Before subject enrollment can commence, the sponsor and site must finalize a clinical trial agreement, establishing legal and ethical commitments." Objectives:
* Ensure proper contractual arrangements before trial initiation.
* Protect legal rights and obligations of involved parties.
NEW QUESTION # 24
An investigator in a multicenter trial reports multiple occurrences of an SAE to the sponsor. Who is responsible for reporting the SAEs to the remaining sites' IRB/IECs?
- A. Regulatory authority
- B. Study sponsor
- C. Original reporting investigator
- D. Investigator at each site
Answer: B
Explanation:
The study sponsor is responsible for disseminating information about SAEs to all participating sites. This ensures consistent and timely communication of safety concerns, allowing each site to take appropriate actions in line with local regulations and IRB/IEC requirements.
The answer aligns with ICH E6(R2) GCP guidelines which mandate the sponsor to communicatesafety information to all investigators and sites involved in a multicenter trial.
"The sponsor must inform all investigators of safety information that could affect the conduct of the trial or the safety of subjects." Objectives:
* Maintain consistent safety reporting across all trial sites.
* Ensure regulatory compliance in multicenter trials.
NEW QUESTION # 25
Who on the local site research study team is accountable for the unblinding documentation of IP?
- A. Pharmacist
- B. Regulatory manager
- C. CRC
- D. PI
Answer: D
Explanation:
The Principal Investigator (PI) is ultimately responsible for maintaining and documenting any unblinding events related to the investigational product (IP). This accountability ensures that any instance where the blind is broken is properly justified, documented, and reported to maintain trial integrity.
GCP guidelines state that the PI must oversee the unblinding process and ensure proper documentation to protect the validity of the trial data.
"The PI is responsible for ensuring that any unblinding of the investigational product is adequately documented and reported according to protocol." Objectives:
* Maintain the integrity of blinded studies.
* Properly document unblinding incidents.
NEW QUESTION # 26
A sponsor writes a protocol comparing an IP XYZ to a marketed drug ABC to determine if XYZ is more efficacious in the target population than ABC. Both drugs are prepared in identically masked IV bags and distributed according to the randomization scheme outlined in the protocol such that the study team is unaware of the treatment assignment.
Which of the following is an appropriate title for this study?
- A. A randomized, open-label, comparator study comparing the efficacy of XYZ to ABC in the target population
- B. A randomized, double-blind, superiority study comparing the efficacy of XYZ to ABC in the target population
- C. A randomized, double-blind, double-dummy, superiority study comparing the efficacy of XYZ to ABC in the target population
- D. A randomized, single-blind, placebo-controlled study comparing the efficacy of XYZ to ABC in the target population
Answer: B
Explanation:
Since both the investigator and the participant are unaware of the treatment assignment, the study is classified as double-blind. The study aims to establish the superiority of XYZ over ABC, making it a superiority study.
The use of masked IV bags confirms the double-blind design.
The answer is verified from GCP guidelines on blinding and superiority study designs.
"In double-blind studies, neither the participant nor the investigator knows the treatment assignment, which prevents bias." Objectives:
* Understanding blinding methods in clinical trials
* Ensuring unbiased efficacy comparisons
NEW QUESTION # 27
The inclusion and exclusion criteria are in place so all subjects are:
- A. Ethically vulnerable and patients with the disease under study.
- B. Medically appropriate and protected from ethical vulnerability.
- C. Healthy and willing to complete the clinical trial.
- D. Patients with the disease under study and will not have any adverse events.
Answer: B
Explanation:
Inclusion and exclusion criteria are designed to ensure that participants are medically appropriate for the study and are not ethically vulnerable. This reduces risks to subjects and ensures that the collected data accurately reflects the target population.
The answer follows GCP principles that emphasize participant safety and data validity through well-defined inclusion/exclusion criteria.
"Inclusion and exclusion criteria are crucial for ensuring the safety of participants and the scientific validity of study results." Objectives:
* Ensuring participant safety.
* Maintaining ethical standards in clinical research.
NEW QUESTION # 28
The PI did not record the relationship to IP in the medical chart when assessing an adverse event. The CRC noticed the omission and brought it to the PI's attention. How should this be addressed?
- A. The CRC should write a note to file.
- B. The PI should amend the medical chart.
- C. The CRC should amend the medical chart.
- D. The PI should notify the monitor.
Answer: B
Explanation:
The PI is responsible for ensuring accurate documentation of adverse events (AEs) in the medical chart, including their relationship to the investigational product (IP). If an omission is identified, the PI must correct it by making a dated and signed amendment to maintain data accuracy and completeness.
GCP guidelines state that the PI must maintain accurate and complete records, including the assessment of the relationship between AEs and the IP.
"The investigator must document the assessment of the relationship between the AE and the investigational product to ensure accurate clinical records." Objectives:
* Maintain accuracy in adverse event documentation.
* Ensure data integrity through appropriate corrections.
NEW QUESTION # 29
Who is responsible for the ongoing safety evaluation of the IP?
- A. PI
- B. Sponsor
- C. IRB/IEC
- D. Regulatory agency
Answer: B
Explanation:
The sponsor is primarily responsible for the ongoing safety evaluation of the investigational product (IP) throughout the clinical trial. This responsibility includes monitoring adverse events, reporting serious adverse events (SAEs) to regulatory authorities, and updating the Investigator's Brochure (IB) with relevant safety data.
According to GCP guidelines, the sponsor must continuously evaluate safety data and report findings to regulatory bodies as necessary.
"The sponsor is responsible for the continuous safety monitoring of the investigational product and for ensuring that new safety information is communicated to investigators and regulators." Objectives:
* Ensure participant safety throughout the study.
* Maintain accurate and timely reporting of safety data.
NEW QUESTION # 30
A study subject inadvertently disposed of IP medication bottles. The site should report this to the:
- A. Medical monitor.
- B. Regulatory authority.
- C. Sponsor.
- D. IRB/IEC.
Answer: C
Explanation:
The loss or disposal of investigational product (IP) must be reported to the sponsor. The sponsor will evaluate the situation and determine the next steps, including whether additional reporting to regulatory authorities or corrective actions are necessary. Reporting to the sponsor ensures that the accountability of the IP is properly documented and managed.
GCP guidelines specify that any loss or disposal of IP should be immediately reported to the sponsor for appropriate action and documentation.
"Any incident involving the loss, mishandling, or disposal of IP should be reported to the sponsor to maintain accurate drug accountability." Objectives:
* Maintain accurate IP accountability.
* Comply with sponsor requirements for IP management.
NEW QUESTION # 31
Who is responsible for submitting a protocol amendment to the IRB/IEC?
- A. Investigator
- B. CRA
- C. Sponsor
- D. CRC
Answer: A
Explanation:
The investigator holds the responsibility for submitting any protocol amendments to the IRB/IEC for review and approval. This step ensures that all changes are ethically evaluated before being implemented, maintaining compliance with regulatory requirements.
According to GCP guidelines, the investigator must submit protocol changes to the IRB/IEC to secure approval before making any modifications to the study.
"The investigator must inform the IRB/IEC of any proposed protocol changes and secure approval prior to implementation." Objectives:
* Maintain ethical oversight in study modifications.
* Adhere to regulatory submission requirements.
NEW QUESTION # 32
A printed, optical, or electronic document designed to record all of the protocol-required information and is transmitted to the sponsor is called a:
- A. Source document.
- B. Worksheet.
- C. PRO.
- D. CRF.
Answer: D
Explanation:
A Case Report Form (CRF) is a tool used in clinical trials to collect data as specified by the protocol. It is a printed, optical, or electronic document designed to record all protocol-required information for each trial subject. CRFs are crucial for ensuring that the data collected during the trial is accurate, complete, and consistent with the protocol.
This answer follows GCP guidelines, which describe CRFs as essential documents for capturing and transmitting study data to the sponsor.
"A Case Report Form (CRF) is a printed, optical, or electronic document specifically designed to record all protocol-required information to be reported to the sponsor on each trial subject." Objectives:
* Understand the role of CRFs in clinical trials.
* Ensure accurate and complete data collection.
NEW QUESTION # 33
A study sponsor approaches a facility about participating in their research study. The study sponsor requires use of social media as its sole method of recruitment. The site knows their institutional IRB/IEC does not approve of social media recruiting. How should the site respond?
- A. Decline the study.
- B. Use a central IRB/IEC.
- C. Recruit for the study without use of social media.
- D. Rely on the sponsor to notify the IRB/IEC.
Answer: A
Explanation:
If the IRB/IEC has a policy that does not permit social media recruiting, the site must adhere to these regulations. Proceeding with a method not approved by the IRB/IEC would violate compliance requirements, so declining the study is the correct course of action.
The answer aligns with IRB/IEC regulations that prioritize ethical and compliant recruitment methods.
"Sites must follow the recruitment methods approved by their IRB/IEC to maintain compliance and ethical standards." Objectives:
* Adhering to ethical recruitment practices.
* Maintaining compliance with IRB/IEC policies.
NEW QUESTION # 34
Who determines the age of assent for pediatric studies?
- A. PI
- B. IRB/IEC
- C. Sponsor
- D. Parent
Answer: B
Explanation:
The IRB/IEC determines the age at which a child is considered capable of providing assent for participation in a clinical trial. This decision is based on local regulations, cultural considerations, and the child's ability to understand the trial's risks and benefits. The age of assent may vary between jurisdictions and is subject to ethical considerations specific to pediatric research.
GCP guidelines emphasize that the IRB/IEC is responsible for setting the criteria for obtaining assent from minors based on ethical and regulatory frameworks.
"The IRB/IEC is responsible for determining the age and circumstances under which pediatric assent is required, considering the child's comprehension level." Objectives:
* Ensure appropriate ethical practices in pediatric research.
* Align with local regulatory requirements for assent.
NEW QUESTION # 35
In order to conduct open-label, parallel group clinical trials according to sound scientific principles, which of the following design elements should be included?
- A. Randomization
- B. Blinding
- C. Privacy controls
- D. Placebo-controlled
Answer: A
Explanation:
Randomization is a key element in open-label, parallel group clinical trials to reduce selection bias and ensure that participant allocation is not influenced by investigators. Despite the absence of blinding in open-label studies, randomization maintains the validity and reliability of the results by evenly distributing confounding factors between groups.
GCP guidelines recommend randomization as a core element in clinical trial design to ensure unbiased allocation of participants.
"Randomization in parallel group trials helps minimize selection bias and ensures the comparability of intervention groups." Objectives:
* Maintain scientific rigor through randomization.
* Minimize selection bias in clinical studies.
NEW QUESTION # 36
A protocol requires participants to take IP for 6 months. The protocol allows for any participants who are noncompliant to be replaced by enrolling additional participants, except if it is due to an AE. The investigator has enrolled 12 participants.
The status of the enrolled participants is as follows:
* 3 participants were withdrawn due to noncompliance
* 1 participant withdrew consent after experiencing severe nausea
* 1 participant had to discontinue IP for an unscheduled hospitalization
* 1 participant who is not returning for visits
* 2 participants completed the 6 months of treatment
* 4 participants currently on IP
How many participants should be replaced?
- A. 4 participants
- B. 3 participants
- C. 6 participants
- D. 5 participants
Answer: B
Explanation:
Since the protocol specifies that participants withdrawn due to an Adverse Event (AE) should not bereplaced, only the participants withdrawn for noncompliance (3 in total) should be replaced. The participant who withdrew consent due to severe nausea (an AE) and the one who discontinued IP due to hospitalization should not be replaced.
GCP guidelines specify that replacement of subjects should follow the protocol criteria, particularly when AEs are involved.
"Participants withdrawn due to AEs should not be replaced if the protocol stipulates this condition, while noncompliant participants may be replaced." Objectives:
* Follow protocol guidelines for participant replacement.
* Ensure compliance with study criteria.
NEW QUESTION # 37
......
Tested Material Used To ACRP-CP: https://exampdf.dumpsactual.com/ACRP-CP-actualtests-dumps.html
